Short answer
Axsome Therapeutics, Inc. (AXSM) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $171M (up 63.2% year over year) with net income of −$47M.
Q3 2025 key financials · XBRL
- Revenue
- $171M
- +63.2% YoY · +14.0% QoQ
- Net income
- −$47M
- +26.9% YoY · +1.6% QoQ
- Operating margin
- -27.0%
- EPS (diluted)
- −$0.95
- +29.1% YoY · +1.0% QoQ
Source: XBRL data from the Axsome Therapeutics, Inc. (AXSM) Q3 2025 10-Q on SEC EDGAR. USD.
Axsome Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Blackstone Loan Agreement with $570M facility triggered by May 8, 2025 closing, includes covenants restricting operations and $30M minimum liquidity covenant
- Most materially updated risk: U.S. political uncertainty with 2025 federal government shutdown and 100% tariff on branded pharmaceuticals starting October 1, 2025, may disrupt operations
- Regulatory/compliance risk: FDA reliance restrictions on safety/efficacy data could cause delays or extra costs in product development and commercialization
- Operational/market risk: Geopolitical conflicts (Russia-Ukraine war, Israel-Hamas hostilities) causing market volatility and supply chain uncertainties impacting near-term performance
- Financial risk: Outstanding loans bear variable SOFR +4.75% interest, maturity May 8, 2030, risk of accelerated repayment upon covenant breach affecting liquidity and business continuity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axsome Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.